Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) reached a new 52-week low on Monday. The stock traded as low as $42.80 and last traded at $43.2020, with a volume of 109956 shares changing hands. The stock had previously closed at $43.54. Wall Street Analyst Weigh In A number of brokerages have issued reports on

Alector (NASDAQ: ALEC - Get Free Report) and Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk. Institutional and Insider Ownership 85.8% of Alector shares are

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.

IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of investigational sefaxersen in adults diagnosed with primary IgA nephropathy (IgAN).

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine protein.

Otsuka Pharmaceutical and Ionis Pharmaceuticals said on Tuesday their experimental drug met the main ​goal of a late-stage study in patients ‌with a rare inherited form of amyotrophic lateral sclerosis, or ALS.

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ionis Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with a genetic subtype of amyotrophic lateral sclerosis (ALS) known as FUS-ALS, caused by mutations in the fused in sarcoma (FUS) gene1. The study met its primary end.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with amyotrophic lateral sclerosis (ALS) caused by mutations in the fused in sarcoma (FUS) gene, also known as FUS-ALS. The study met its primary endpoint, with ulefnersen demonstrating a statistical.

Ionis has six commercial therapies, mostly focused on rare diseases. Zanvastro treats Alexander disease, a brain disorder.